Antigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral Leishmaniasis

Martins, Vívian T.; Chávez-Fumagalli, Miguel Á.; Lage, Daniela P.; Duarte, Mariana C.; Garde, Esther; Costa, Lourena E.; Silva, Viviane Grazielle da; Oliveira, Jamil S.; Magalhães-Soares, Danielle F. de; Teixeira, Santuza Maria Ribeiro; Fernandes, Ana Paula; Soto, Manuel; Tavares, Carlos Alberto Pereira; Coelho, Eduardo Antônio Ferraz

doi:10.1371/journal.pone.0137683

Cited by 21 publications

(31 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The protection was correlated with parasite-specific and dependent IFN-γ production, mainly by CD4 + T cells, which were the major source of IFN-γ in these animals (14) .The same immune profi le was found when the hypothetical LiHyD (31) , LiHyT (32) , LiHyp6 (55) , and LiHyV (84) proteins were evaluated as vaccine candidates. In all cases, the antigens were shown to be protective against infection, since vaccinated and challenged animals presented signifi cantly lower parasite levels in evaluated organs compared with control groups.…”

Section: Tablementioning

confidence: 59%

“…The infected and vaccinated animals showed signifi cant reductions in parasite burden in the various organs evaluated compared with control mice, the protection being associated with IL-12-dependent IFN-γ production against parasite extracts, and correlated with the induction of antileishmanial nitrite production. More importantly, this polyprotein vaccine was able to induce a more robust Th1 response associated with better control of parasite dissemination in the organs of the vaccinated animals, compared with the use of the individual recombinant proteins (55) .…”

Section: Tablementioning

confidence: 99%

“…It has been postulated that a formulation containing different Leishmania proteins expressed in both parasite stages should provide better results, in terms of a more effective and protective vaccine against VL (42) (55) . The use of vaccines combining different proteins could provide the benefi ts of increased simplicity and reduced production costs, since it would only be necessary to produce a single vaccine to protect against different Leishmania species (56) .…”

Section: Second-generation Vaccines Against Visceral Leishmaniasismentioning

confidence: 99%

See 2 more Smart Citations

Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis

Duarte

Lage

Martins

et al. 2016

Rev. Soc. Bras. Med. Trop.

Self Cite

View full text Add to dashboard Cite

Visceral leishmaniasis (VL) is one of the most important tropical diseases worldwide. Although chemotherapy has been widely used to treat this disease, problems related to the development of parasite resistance and side effects associated with the compounds used have been noted. Hence, alternative approaches for VL control are desirable. Some methods, such as vector control and culling of infected dogs, are insuffi ciently effective, with the latter not ethically recommended. The development of vaccines to prevent VL is a feasible and desirable measure for disease control; for example, some vaccines designed to protect dogs against VL have recently been brought to market. These vaccines are based on the combination of parasite fractions or recombinant proteins with adjuvants that are able to induce cellular immune responses; however, their partial effi cacy and the absence of a vaccine to protect against human leishmaniasis underline the need for characterization of new vaccine candidates. This review presents recent advances in control measures for VL based on vaccine development, describing extensively studied antigens, as well as new antigenic proteins recently identifi ed using immuno-proteomic techniques.

show abstract

Section: Tablementioning

confidence: 59%

Section: Tablementioning

confidence: 99%

Section: Second-generation Vaccines Against Visceral Leishmaniasismentioning

confidence: 99%

See 1 more Smart Citation

Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis

Duarte

Lage

Martins

et al. 2016

Rev. Soc. Bras. Med. Trop.

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Vaccine For Protozoamentioning

confidence: 99%

“…In recent times a polyproteins vaccine when administered in association with an adjuvant, provide protection against VL. This vaccine has two Leishmania infantum hypothetical proteins present in the amastigote stage, LiHyp1 and LiHyp6, were combined with a promastigote protein, IgE-dependent histamine-releasing factor (HRF) [64,65].Amebiasis Vaccine: Entamoeba spp mainly causes diarrhea (watery or contains blood and mucus) and vomiting. In case of mammalian cells the binding of trophozoites of Entamoeba histolytica is mediated by a protein (serine rich).…”

mentioning

confidence: 99%

Mammalian Parasitic Vaccine: A Consolidated Exposition

Sumbria¹,

Singla²

2015

J Vaccines Immun

View full text Add to dashboard Cite

Parasites are highly prevalent in livestock worldwide and infect over one fourth of the human population also. Parasites are successful in evading host immune responses, and vaccination can prove to be an effective way to control them. However, currently very few vaccines are available against parasitic infection. Two important limitations in the emergence of effective parasitic vaccines are incomplete understanding of the immunoregulatory pathways involved in immunity, and the lack of precise information regarding host-pathogen interactions. Precise identification of parasite genes and the role of their products in parasite biology may assist in the identification of useful antigens, which could then be produced in recombinant systems. Many recombinant parasitic antigens have been successfully used in livestock and new vaccines are under trail. Numerous vaccine antigens are defined to target a wide range of parasite species. Thus vaccines offer a green solution to control disease. Vaccines have multiple beneficial effects such as improvement of animal health and welfare by controlling animal infestations and infections; diminishing resistance to anthelmintics, acaricides and antibiotics; improving public health status by controlling food borne pathogens and zoonoses aspect related to animals; keeping animals and the environment free of chemical residues and maintaining biodiversity. This current review is an attempt to consolidate all commercial or under-trail vaccine for mammalian parasites.$ 64.6 million are lost in productivity losses. The average total costs for persons with mild, moderate, and severe illness were $116, $475, and $7,808, respectively [7,8]. In order to come out from adverse effect of these parasites an urge of effective control is needed. Up till now the control strategy of parasites relies mainly on the use of chemotherapy like anthelminthes, antiprotozoal drugs and insecticides etc, as they are safe, cheap and effective against a broad spectrum of parasites [9,10]. But indiscriminate use of these drugs led to the emergence of drug resistance in many targeted parasites [11]. On the same time, issues of residues in the food chain and environment have arisen, which threaten their sustained use [12]. So scientist and researcher are now a days concentrating on development of alternate sustainable methods like vaccinations, novel therapeutic regimens and immnuomodulations against these parasite [2]. The term "vaccine" was first coined by Edward Jenner in 1881; it was derived from Variolae vaccinae (smallpox of the cow). Vaccines are used to generate antibodies and boost immunity against a disease, and usually contain an agent which may be the microorganism, its product, toxins or one of its surface proteins, treated/modified to be used as an antigen without causing disease [13]. It can be prophylactic or therapeutic. Vaccination helps in the development of acquired immunity by inoculating non-pathogenic but immunogenic components of the pathogen, or closely related organisms. In animal ...

show abstract

Vaccines for Canine Leishmaniasis

Coelho

Christodoulides

2023

Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges

View full text Add to dashboard Cite

Visceral leishmaniasis is a zoonotic disease in many countries and dogs are considered the main domestic reservoir of Leishmania parasites, and the presence of infected animals represents a potential risk for human disease. In this chapter, we review the state-of-the-art of canine visceral leishmaniasis (CanL) vaccines, discussing the properties and problems associated with the few currently licensed and discontinued vaccines and looking forward to the development of new, more effective vaccines. Reducing the incidence of CanL through vaccination will improve canine health and welfare and contribute to preventing human VL.

show abstract

Antigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral Leishmaniasis

Cited by 21 publications

References 70 publications

Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis

Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis

Mammalian Parasitic Vaccine: A Consolidated Exposition

Vaccines for Canine Leishmaniasis

Contact Info

Product

Resources

About